These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38029026)

  • 1. Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas.
    Rajendran M; Rao M; Elhence PA; Bharti JN; Singh P; Yadav G; Nalwa A; Goyal AD
    J Midlife Health; 2023; 14(2):81-86. PubMed ID: 38029026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic characteristics, tumor infiltrating lymphocytes and programed cell death ligand-1 expression in 162 endometrial carcinomas with deficient mismatch repair function.
    Chavez JA; Wei L; Suarez AA; Parwani AV; Li Z
    Int J Gynecol Cancer; 2019 Jan; 29(1):113-118. PubMed ID: 30640692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
    Özcan D; Lade-Keller J; Tramm T
    Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
    Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
    World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
    Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
    Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
    Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
    Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
    Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
    Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3.
    Wu S; Shi X; Wang J; Wang X; Liu Y; Luo Y; Mao F; Zeng X
    Front Immunol; 2021; 12():561793. PubMed ID: 33717059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.
    Feng YC; Ji WL; Yue N; Huang YC; Ma XM
    Cancer Manag Res; 2018; 10():105-113. PubMed ID: 29403308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
    Rowe M; Krishnan R; Mills A; Ring K
    Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
    Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
    Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study.
    Wahba MG; Soliman SS; Salama ME; Nasr S; Al Shereef ZAE
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1441-1450. PubMed ID: 38680006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD169
    Saito Y; Fujiwara Y; Miyamoto Y; Ohnishi K; Nakashima Y; Tabata Y; Baba H; Komohara Y
    Cancer Med; 2023 May; 12(9):10199-10211. PubMed ID: 36846928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
    Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
    Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma.
    Jiang D; Song Q; Wei X; Yu Z; Liu Y; Wang H; Wang X; Huang J; Su J; Hong Y; Xu Y; Xu C; Hou Y
    Front Oncol; 2022; 12():897527. PubMed ID: 35865481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
    Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
    Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.